Experience of anti-relapse therapy for ovarian endometriosis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To evaluate the efficacy of a gonadotropin-releasing hormone (GnRH) agonist (Buserelin depot) in reducing the recurrence rate of ovarian endometriosis after surgery. Subjects and methods. A total of 147 patients with a verified diagnosis of ovarian endometriosis were examined. The inclusion criterion was also the patients’ reproductive age: the latter ranging from 27 to 35 years was preponderant in the study group; and the mean age of the patients was 31.76±5.84 years. The exclusion criterion was concomitant genital diseases. Results. The use of Buserelin depot did not result in a decrease in anti-Müllerian hormone levels. That also showed a 4.1-fold reduction in the recurrence rate of ovarian endometriosis in the first year after surgery. Conclusion. It is necessary to perform anti-relapse therapy using GnRH agonists (buserelin-depot) after surgical treatment for ovarian endometriosis. The frequency of adverse events was rare and did not exceed 6.25%.

Full Text

Restricted Access

About the authors

Sergey A. Levakov

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: levakoff@yandex.ru
MD, professor, head of the Department of Obstetrics and Gynecology, Faculty of Medicine

Pavel V. Budanov

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Email: pbumer@mail.ru
MD, professor of the Department of Obstetrics and Gynecology, Faculty of Medicine

Tatyana A. Gromova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

postgraduate student, Department of Obstetrics and Gynecology, Faculty of Medicine

Maria V. Yurova

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

student of the faculty of medicine

References

  1. Адамян Л.В., Андреева Е.Н., Аполихина И.А., Беженарь Е.Ф., Геворкян Е.А., Гус А.И., Демидов В.Н., Калинина Е.А., Леваков С.А., Марченко Л.А., Попов А.А., Сонова М.М., Стеняева Н.Н., Филиппов О.С., Хашукоева А.З., Чернуха Г.Е., Яроцкая Е.Л. Эндометриоз: диагностика, лечение и реабилитация. Федеральные клинические рекомендации по ведению больных. М.: Российское общество акушеров-гинекологов; 2013.
  2. Brown J., Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst. Rev. 2014; (3): CD009590.
  3. Benagiano G., Brosens I., Lippi D. The history of endomertiosis. Gynecol. Obstet. Invest. 2014; 78(1): 1-9.
  4. Оразов М.Р. Дискутабельные вопросы эндометриоза. Акушерство и гинекология: новости, мнения, обучение. 2016; 3: 72-84.
  5. Печеникова В.А., Акопян Р.А. Эволюция взглядов на этиопатогенез внутреннего и наружного генитального эндометриозов. Вестник Российской военно-медицинской академии. 2018; 2: 234-9.
  6. Hwang H., Chung Y.J., Lee S.R., Park H.T., Song J.Y., Kim H. et al. Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis. Obstet. Gynecol. Sci. 2018; 61(5): 553-64.
  7. Адамян Л.В., Сонова М.М., Тихонова Е.С., Зимина Э.В., Антонова С.О. Медицинские и социальные аспекты генитального эндометриоза. Проблемы репродукции. 2011; 17(6): 78-81.
  8. Борисова А.В., Козаченко А.В., Франкевич В.Е., Чаговец В.В., Кононихин А. С., Стародубцева Н.Л., Коган Е.А., Адамян Л.В. Факторы риска развития рецидива наружного генитального эндометриоза после оперативного лечения: проспективное когортное исследование. Медицинский совет. 2018; 7: 32-8.
  9. Strygina V.A., Solomatina A.A., Bulatova L.S., Sadovnikova E.A., Hamzin I.Z. Recurrence of ovarian endometriosis. Вопросы гинекологии, акушерства и перинатологии. 2015; 14(6): 29-33.
  10. Dunselman G.A., Vermeulen N., Becker C., Calhaz-Jorge C., D’Hooghe T., De Bie B. et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12.
  11. Адамян Л.В., Азнаурова Я.Б. Молекулярные аспекты патогенеза эндометриоза. Проблемы репродукции. 2015: 21(2): 66-77.
  12. Прилепская В.Н., Иванова Е.В., Тагиева А.В., Летуновская А.Б. Эндометриоз: от трудностей диагностики к новым возможностям терапии. Гинекология. 2012; 14(4): 4-8.
  13. Громова Т.А., Шешукова Н.А., Большакова О.В., Зайратьянц О.В., Леваков С.А., Федотов Е.В. Возможность неопластической трансформации эндометриоза яичников. Акушерство и гинекология. 2018; 3: 96-101.
  14. Gibson D.A., Simitsidellis I., Collins F., Saunders P.T.K. Endometrial intracrinology: oestrogens, androgens and endometrial disorders. Int. J. Mol. Sci. 2018; 19(10). pii: E3276.
  15. Громова Т.А., Леваков С.А. Современные аспекты в лечении эндометриоза и в профилактике его рецидивирующих форм. Medicus. 2016; 3: 46-9.
  16. Brown J., Farquhar C. An overview of treatments for endometriosis. JAMA. 2015; 313(3): 296-7.
  17. Brown J., Pan A., Hart R.J. Gonadotrophin-releasing hormone analogues for pain associated with endometriosis. Cochrane Database Syst. Rev. 2010; (12): CD008475.
  18. Беженарь В.Ф., Ярмолинская М.И., Байлюк Е.Н., Цыпурдеева А.А., Цицкарава Д.З., Моругина Е.В., Постникова Т.Б., Орехова Е.К. Сравнение эффективности различных схем гормономодулирующей терапии после хирургического лечения наружного генитального эндометриоза. Проблемы репродукции. 2015; 21(4): 89-98.
  19. Piepenbrink A., Failing K., Riesenbeck A., Schmid P., Hoffmann B. Downregulation of LH in the bitch after application of the GnRH-agonist buserelin as a slow-release implant. Tierarztl. Prax. Ausg. K. Kleintiere Heimtiere. 2017; 45(3): 147-52.
  20. Altarac S. Histrelin acetate--the first once yearly LHRH agonist. Lijec. Vjesn. 2011; 133(9-10): 320-2.
  21. Юренева С.В., Моисеев С.В. Негормональные методы лечения вазомоторных симптомов менопаузы с позиции медицины, основанной на доказательствах. Клиническая фармакология и терапия. 2010; 19(2): 69-74.
  22. Denny E., Weckesser A., Jones G., Bibila S., Daniels J., Bhattacharya S.; PREEMPT team. Women’s experiences of medical treatment for endometriosis and its impact on PRE-EMPT trial participation: a qualitative study. Pilot Feasibility Stud. 2018; 4: 168.
  23. Lethaby A., Puscasiu L., Vollenhoven B. Preoperative medical therapy before surgery for uterine fibroids. Cochrane Database Syst. Rev. 2017; (11): CD000547.
  24. Немченко О.И. Новые возможности терапии вегетативных проявлений тревоги у гинекологических больных. Гинекология. 2010; 9(3): 54-60.
  25. Zheng W., Cao L., Xu Z., Ma Y., Liang X. Anti-angiogenic alternative and complementary medicines for the treatment of endometriosis: a review of potential molecular mechanisms. Evid. Based Complement. Alternat. Med. 2018; 2018: 4128984.
  26. Fu J., Song H., Zhou M., Zhu H., Wang Y., Chen H., Huang W. Progesterone receptor modulators for endometriosis. Cochrane Database Syst. Rev. 2017; (7): CD009881.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies